Piper Jaffray Companies cut shares of Endologix (NASDAQ:ELGX) from an overweight rating to a neutral rating in a research note published on Friday, Marketbeat reports.

A number of other equities research analysts also recently weighed in on ELGX. ValuEngine upgraded shares of Endologix from a strong sell rating to a sell rating in a research note on Wednesday, May 2nd. BidaskClub upgraded shares of Endologix from a hold rating to a buy rating in a research note on Thursday, May 3rd. Oppenheimer set a $5.00 price target on shares of Endologix and gave the stock a hold rating in a research note on Thursday, May 3rd. Zacks Investment Research upgraded shares of Endologix from a sell rating to a hold rating in a research note on Monday, May 7th. Finally, Stifel Nicolaus lifted their price target on shares of Endologix from $4.50 to $5.00 and gave the stock a hold rating in a research note on Monday, May 21st. One research analyst has rated the stock with a sell rating and nine have given a hold rating to the stock. The company presently has a consensus rating of Hold and an average price target of $4.00.

Shares of Endologix stock opened at $2.74 on Friday. Endologix has a 1 year low of $2.66 and a 1 year high of $6.72. The company has a debt-to-equity ratio of 5.37, a quick ratio of 1.20 and a current ratio of 1.90.

Endologix (NASDAQ:ELGX) last posted its quarterly earnings results on Thursday, August 9th. The medical instruments supplier reported ($0.18) earnings per share for the quarter, hitting the Zacks’ consensus estimate of ($0.18). Endologix had a negative net margin of 40.92% and a negative return on equity of 69.06%. The firm had revenue of $44.70 million for the quarter, compared to the consensus estimate of $44.43 million. During the same quarter in the previous year, the company earned ($0.10) earnings per share. The business’s revenue was down 8.0% compared to the same quarter last year. equities analysts anticipate that Endologix will post -0.7 earnings per share for the current year.

A number of institutional investors and hedge funds have recently bought and sold shares of ELGX. Deutsche Bank AG boosted its stake in shares of Endologix by 111.7% in the 4th quarter. Deutsche Bank AG now owns 190,868 shares of the medical instruments supplier’s stock valued at $1,019,000 after purchasing an additional 100,703 shares in the last quarter. Geode Capital Management LLC boosted its stake in shares of Endologix by 3.5% in the 4th quarter. Geode Capital Management LLC now owns 721,491 shares of the medical instruments supplier’s stock valued at $3,859,000 after purchasing an additional 24,703 shares in the last quarter. Schwab Charles Investment Management Inc. boosted its stake in shares of Endologix by 8.7% in the 1st quarter. Schwab Charles Investment Management Inc. now owns 380,648 shares of the medical instruments supplier’s stock valued at $1,611,000 after purchasing an additional 30,585 shares in the last quarter. Altrinsic Global Advisors LLC boosted its stake in shares of Endologix by 9.5% in the 1st quarter. Altrinsic Global Advisors LLC now owns 1,035,000 shares of the medical instruments supplier’s stock valued at $4,378,000 after purchasing an additional 90,000 shares in the last quarter. Finally, BNP PARIBAS ASSET MANAGEMENT Holding S.A. boosted its stake in shares of Endologix by 14.0% in the 2nd quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 1,431,962 shares of the medical instruments supplier’s stock valued at $8,105,000 after purchasing an additional 175,970 shares in the last quarter. Hedge funds and other institutional investors own 97.96% of the company’s stock.

Endologix Company Profile

Endologix, Inc develops, manufactures, markets, and sells medical devices for the treatment of abdominal aortic aneurysms in the United States and internationally. It offers minimally-invasive endovascular repair (EVAR) products, including AFX (Anatomical Fixation) endovascular AAA system, which is a minimally invasive delivery system; VELA Proximal Endograft, which is designed for the treatment of proximal aortic neck anatomies with AFX; and the ovation abdominal stent graft system.

Featured Article: Diversification Important in Investing

Analyst Recommendations for Endologix (NASDAQ:ELGX)

Receive News & Ratings for Endologix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Endologix and related companies with MarketBeat.com's FREE daily email newsletter.